Indoleamine 2,3-dioxygenase is increased in hemodialysis patients and affects immune response to hepatitis B vaccination

Vaccine

Volumn 29, Issue 12, 2011, Pages 2242-2247

  Eleftheriadis, Theodoros ^a,b   Liakopoulos, Vassilios ^a   Antoniadi, Georgia ^a   Stefanidis, Ioannis ^a   Galaktidou, Grammati ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

HBV; Hemodialysis; Immune response; Indoleamine 2,3 dioxygenase; Inflammation; Vaccine

Indexed keywords

C REACTIVE PROTEIN; HEPATITIS B SURFACE ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 6; RECOMBINANT HEPATITIS B VACCINE; SERUM ALBUMIN; TUMOR NECROSIS FACTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VACCINATION;

ADAPTIVE IMMUNITY; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-6; MALE; MIDDLE AGED; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951812426     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.051     Document Type: Article

References (48)

1. Eleftheriadis T., Antoniadi G., Liakopoulos V., Kartsios C., Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20(5 (September-October)):440-451.
2. Eleftheriadis T., Tsiaga P., Antoniadi G., Liakopoulos V., Kortsaris A., Giannatos E., et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. Am J Kidney Dis 2005, 46(4 (October)):706-712.
3. Eleftheriadis T., Papazisis K., Kortsaris A., Vayonas G., Voyatzi S., Vargemezis V. Impaired T cell proliferation and zeta chain phosphorylation after stimulation with staphylococcal enterotoxin-B in hemodialysis patients. Nephron Clin Pract 2004, 96(1):c15-c20.
4. Stachowski J., Pollok M., Burrichter H., Spithaler C., Baldamus C.A. Signalling via the TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. Nephron 1993, 64(3):369-375.
5. Stachowski J., Pollok M., Barth C., Maciejewski J., Baldamus C.A. Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 1994, 9(2):144-152.
6. Girndt M., Kohler H., Schiedhelm-Weick E., Meyer zum Buschenfelde K.H., Fleischer B. T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993, 44(2 (August)):359-365.
7. Girndt M., Sester M., Sester U., Kaul H., Kohler H. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001, 59(4 (April)):1382-1389.
8. Contin C., Pitard V., Delmas Y., Pelletier N., Defrance T., Moreau J.F., et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003, 110(1 (September)):131-140.
9. Eleftheriadis T., Kartsios C., Yiannaki E., Kazila P., Antoniadi G., Liakopoulos V., et al. Chronic inflammation and T cell zeta-chain downregulation in hemodialysis patients. Am J Nephrol 2008, 28(1):152-157.
10. Ori Y., Korzets A., Malachi T., Gafter U., Breitbart H. Impaired lymphocyte calcium metabolism in end-stage renal disease: enhanced influx, decreased efflux, and reduced response to mitogen. J Lab Clin Med 1999, 133(4 (April)):391-400.
11. Sester U., Sester M., Hauk M., Kaul H., Kohler H., Girndt M. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000, 15(8 (August)):1217-1223.
12. Meier P., Dayer E., Blanc E., Wauters J.P. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol 2002, 13(1 (January)):204-212.
13. Fernandez-Fresnedo G., Ramos M.A., Gonzalez-Pardo M.C., de Francisco A.L., Lopez-Hoyos M., Arias M. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000, 5(4 (April 1)):502-510.
14. King N.J., Thomas S.R. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007, 39(12):2167-2172.
15. Mulley W.R., Nikolic-Paterson D.J. Indoleamine 2,3-dioxygenase in transplantation. Nephrology (Carlton) 2008, 13(3 (June)):204-211.
16. Curti A., Trabanelli S., Salvestrini V., Baccarani M., Lemoli R.M. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood 2009, 113(11 (March 12)):2394-2401.
17. Alexander A.M., Crawford M., Bertera S., Rudert W.A., Takikawa O., Robbins P.D., et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002, 51(2 (February)):356-365.
18. Beutelspacher S.C., Pillai R., Watson M.P., Tan P.H., Tsang J., McClure M.O., et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006, 36(3 (March)):690-700.
19. Li Y., Tredget E.E., Ghaffari A., Lin X., Kilani R.T., Ghahary A. Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 2006, 126(1 (January)):128-136.
20. Seo S.K., Choi J.H., Kim Y.H., Kang W.J., Park H.Y., Suh J.H., et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004, 10(10 (October)):1088-1094.
21. Gurtner G.J., Newberry R.D., Schloemann S.R., McDonald K.G., Stenson W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 2003, 125(6 (December)):1762-1773.
22. Kwidzinski E., Bunse J., Aktas O., Richter D., Mutlu L., Zipp F., et al. Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J 2005, 19(10 (August)):1347-1349.
23. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380 (August 21)):1191-1193.
24. Mellor A.L., Sivakumar J., Chandler P., Smith K., Molina H., Mao D., et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001, 2(1 (January)):64-68.
25. Hayashi T., Beck L., Rossetto C., Gong X., Takikawa O., Takabayashi K., et al. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 2004, 114(2 (July)):270-279.
26. Brandacher G., Cakar F., Winkler C., Schneeberger S., Obrist P., Bosmuller C., et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007, 71(1 (January)):60-67.
27. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117(5 (May)):1147-1154.
28. Schefold J.C., Zeden J.P., Fotopoulou C., von Haehling S., Pschowski R., Hasper D., et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant 2009, 24(6 (June)):1901-1908.
29. Pawlak K., Brzosko S., Mysliwiec M., Pawlak D. Kynurenine, quinolinic acid-the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis 2009, 204(2 (June)):561-566.
30. Kato A., Suzuki Y., Suda T., Suzuki M., Fujie M., Takita T., et al. Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients. Hemodial Int 2010, 14(4):418-424.
31. Saito K., Fujigaki S., Heyes M.P., Shibata K., Takemura M., Fujii H., et al. Mechanism of increases in l-kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol 2000, 279(3 (September)):F565-F572.
32. Pawlak D., Tankiewicz A., Matys T., Buczko W. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol 2003, 54(2 (June)):175-189.
33. Bologa R.M., Levine D.M., Parker T.S., Cheigh J.S., Serur D., Stenzel K.H., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998, 32(1):107-114.
34. Stenvinkel P., Heimburger O., Lindholm B., Kaysen G.A., Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000, 15(7 (July)):953-960.
35. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984, 311(8 (August 23)):496-501.
36. Buti M., Viladomiu L., Jardi R., Olmos A., Rodriguez J.A., Bartolome J., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992, 12(3):144-147.
37. Dinits-Pensy M., Forrest G.N., Cross A.S., Hise M.K. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005, 6(6 (December 4)):997-1011.
38. Charest A.F., Grand'Maison A., McDougall J., Goldstein M.B. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am J Kidney Dis 2003, 42(6 (December)):1193-1199.
39. Tsouchnikas I., Dounousi E., Xanthopoulou K., Papakonstantinou S., Thomoglou V., Tsakiris D. Loss of hepatitis B immunity in hemodialysis patients acquired either naturally or after vaccination. Clin Nephrol 2007, 68(4 (October)):228-234.
40. Peces R., de la Torre M., Alcazar R., Urra J.M. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997, 2 (February 29):239-245.
41. Ibrahim S., el-Din S., Bazzal I. Antibody level after hepatitis-B vaccination in hemodialysis patients: impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status. J Natl Med Assoc 2006, 98(12 (December)):1953-1957.
42. Kushner I. Regulation of the acute phase response by cytokines. Perspect Biol Med 1993, 36(4 (Summer)):611-622.
43. Fallarino F., Grohmann U., You S., McGrath B.C., Cavener D.R., Vacca C., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006, 176(11 (June 1)):6752-6761.
44. Manlapat A.K., Kahler D.J., Chandler P.R., Munn D.H., Mellor A.L. Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol 2007, 37(4 (April)):1064-1071.
45. Muller A.J., Sharma M.D., Chandler P.R., Duhadaway J.B., Everhart M.E., Johnson B.A., et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008, 105(44 (November 4)):17073-17078.
46. Thomas S.R., Stocker R. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep 1999, 4(5):199-220.
47. Liu H., Liu L., Fletcher B.S., Visner G.A. Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am J Respir Crit Care Med 2006, 173(5 (March 1)):566-572.
48. Sharma M.D., Hou D.Y., Liu Y., Koni P.A., Metz R., Chandler P., et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009, 113(24 (June 11)):6102-6111.